Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity

Overview of attention for article published in Annals of Hematology, January 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter: 5 X users

patent: 1 patent

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 38 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 25,230 followers.

Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. https://t.co/X3je0JffKu. Retrospective data of 5 patients. Dose used was 100 mg in most.

17 Aug 2022

Reply Repost Favourite

RT @graham74GC: Interesting small study - low dose pembro maybe very active in Hodgkin. Would be a lot cheaper too! #lymsm https://t.co/tp4…

02 Feb 2017

Reply Repost Favourite

efficacy with 100mg sounds amazing https://t.co/MkPZaWfKWf

01 Feb 2017

Reply Repost Favourite

Interesting small study - low dose pembro maybe very active in Hodgkin. Would be a lot cheaper too! #lymsm https://t.co/tp4tWraJth

01 Feb 2017

Reply Repost Favourite

Low-dose #pembrolizumab for relapsed/refractory Hodgkin #lymphoma: high efficacy with minimal toxicity NCBI https://t.co/2rNK3PAX6C

01 Feb 2017

Reply Repost Favourite